Prenatal screening for Down syndrome: Current and future methods

Clinics in Laboratory Medicine

Volumn 23, Issue 2, 2003, Pages 395-411

  Canick, Jacob A ^a   Saller Jr , Devereux N ^b   Lambert Messerlian, Geralyn M ^a  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

BIRTH DEFECT; CHROMOSOME ABERRATION; DECISION MAKING; DOWN SYNDROME; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; NON INVASIVE MEASUREMENT; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; SECOND TRIMESTER PREGNANCY; SMITH LEMLI OPITZ SYNDROME; TRISOMY 18;

EID: 0037772456     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(03)00025-8     Document Type: Review

References (59)

1. Wald N. Neural tube defects. In: Wald N, Leck I, editors, Antenatal and neonatal screening. 2nd edition, Oxford, UK: Oxford University Press; 2000. p. 61-84.
2. Palomaki GE, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM. Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am J Obstet Gynecol 1997;176:1046-51.
3. Wald N. Preface to the second edition. In: Wald N, Leck I, editors. Antenatal and neonatal screening. 2nd edition. Oxford, UK: Oxford University Press; 2000. p. xi-xii.
4. Ward OC. John Langdon Down: a caring pioneer. London, UK: The Royal Society of Medicine Press Ltd.; 1988.
5. Noble J. Natural history of Down's syndrome: a brief review for those involved in antenatal screening. J Med Screen 1998;5:172-7.
6. Wald N. Down's syndrome. In: Wald N, Leck I, editors. Antenatal and neonatal screening. 2nd edition. Oxford, UK: Oxford University Press; 2000. p. 85-115.
7. Penrose LS. The relative effects of paternal and maternal age in mongolism. J Genet 1933;27:219-24.
8. Valenti C, Schutta EJ, Kehaty T. Prenatal diagnosis of Down's syndrome. Lancet 1968;ii:220.
9. Wald NJ. The detection of neural-tube defects by screening maternal blood. In: Boue A, editor. Prenatal diagnosis. France: INSERM; 1976. p. 227-38.
10. Merkatz IR, Nitowsky HM, Macri JN, et al. An association between low maternal serum alpha-fetoprotein and fetal chromosome abnormalities. Am J Obstet Gynecol 1984;148:886-94.
11. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement. A screening test for Down syndrome. Lancet 1984;i:926-9.
12. New England Regional Genetics Group Prenatal Collaborative Study of Down's Syndrome Screening. Combining maternal serum α feto-protein measurements and age to screen Down's syndrome in pregnant women under age 35. Am J Obstet Gynecol 1989;160:575-81.
13. Wald NJ, Kennard A, Hackshaw A, et al. Antenatal screening for Down's syndrome. J Med Screen 1997;4:181-246.
14. Canick J, Knight GJ, Palomaki GE, et al. Low second trimester maternal serum unconjugated estriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988;95:330-3.
15. Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. Br J Obstet Gynaecol 1988;95:334-41.
16. Bogart M, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987;7:623-30.
17. Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883-97.
18. Macri JN, Kasturi RV, Krantz DA, et al. Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin. Am J Obstet Gynecol 1990;163:1248-53.
19. Wald NJ, Densem JW, Smith D, Klee GG. Four marker serum screening for Down's syndrome. Prenat Diagn 1994;14:707-16.
20. Aitken DA, Wallace EM, Crossley JA, et al. Dimeric inhibin-A as a marker for Down's syndrome in early pregnancy. N Engl J Med 1996;334:1231-6.
21. Knight GJ, Palomaki GE, Neveux L, et al. hCG and the free β-subunit as screening tests for Down syndrome. Prenat Diagn 1998;18:235-46.
22. Wald NJ, Hackshaw AK, George LM. Assay precision of serum α fetoprotein in antenatal screening for neural tube defects and Down's syndrome. J Med Screen 2000;7:74-7.
23. Stranc LC, Evans JA, Hamerton JL. Chorionic villus sampling and amniocentesis for prenatal diagnosis. Lancet 1997;349:711-4.
24. Wald NJ, Hackshaw A, Stone R, et al. Serum alpha-fetoprotein and neural tube defects in the first trimester of pregnancy. Prenat Diagn 1993;13:1047-50.
25. Canick JA, Kellner LH. First trimester screening for aneuploidy: serum biochemical markers. Semin Perinat 1999;23:359-68.
26. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997;17:821-30.
27. Spencer K, Macri JN, Aitken DA, Connor JM. Free β-hCG as a first trimester marker for fetal trisomy. Lancet 1992;339:1480.
28. Brambati B, Macintosh MCM, Teisner B. Low maternal serum levels of PAPP-A in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol 1993;100:324-6.
29. Szabo J, Gellen J. Nuchal fluid accumulation in trisomy 21 detected by vaginosonography in first trimester. Lancet 1990;336:1133.
30. Nicolaides KH, Azar G, Byrne D, et al. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304:867-9.
31. D'Alton ME. Ultrasound in obstetrics and gynecology: an imaging revolution. Contemp Obstet Gynecol 1998;43:67-84.
32. Jaffe R, Abramowicz JS. Manual of obstetric and gynecologic ultrasound. Philadelphia: Lippincott-Raven; 1997.
33. Kornman LH, Morssink LP, Beekhuis JR, et al. Nuchal translucency cannot be used as a screening test for chromosome abnormalities in the first trimester of pregnancy in a routine ultrasound practice. Prenat Diagn 1996;16:797-806.
34. Mol BWJ, Lijmer JG, van der Meulen J, et al. Effect of study design on the association between nuchal translucency measurement and Down syndrome. Obstet Gynecol 1999;94:864-9.
35. Haddow JE, Palomaki GE, Knight GJ, et al. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 1998;338:955-61.
36. Stewart TL, Malone FD. First trimester screening for aneuploidy: nuchal translucency sonography. Semin Perinat 1999;23:369-81.
37. American College of Obstetricians and Gynecologists (ACOG). Prenatal diagnosis of fetal chromosomal abnormalities [ACOG practice bulletin number 27]. May 2001.
38. Knight GJ, Palomaki GE, Neveux LM, Fodor KK, Haddow JE. hCG and the free beta-subunit as screening tests for Down syndrome. Prenat Diagn 1998;18:235-45.
39. Rausch DN, Lambert-Messerlian GM, Canick JA. Participation in maternal serum screening following screen positive results in a previous pregnancy. J Med Screen 2000;7:4-6.
40. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med 1999;341:461-7.
41. Hook EB, Cross PK, Schreinemachers DM. Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA 1983;249:2034-8.
42. Hook EB, Topol BB, Cross PK, The natural history of cytogenetically abnormal fetuses detected at midtrimester amniocentesis which are not terminated electively: new data and estimates of the excess and relative risk of later fetal death associated with 47, + 21 and some other abnormal karyotypes. Am J Hum Genet 1989;45:855-61.
43. Palomaki GE, Haddow JE, Knight GE, et al. Risk-based screening for trisomy 18 using alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. Prenat Diagn 1995;15:713-23.
44. Canick JA, Palomaki GE, Osathanondh R. Prenatal screening for trisomy 18 in the second trimester, Prenat Diagn 1990;10:546-7.
45. Spencer K, Nicolaides KH. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A. Prenat Diagn 2002;22:877-9.
46. Saller DN Jr, Canick JA, Schwartz S, et al. Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome. Am J Obstet Gynecol 1992;167:1021-4.
47. Lambert-Messerlian GM, Saller DN, Tumber MB, et al. Second trimester maternal serum and inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. Prenat Diagn 1998;18:1061-7.
48. Benn PA, Gainey A, Ingardia CJ, et al. Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement. Prenat Diagn 2001;21:680-6.
49. Oyer CE, Canick JA. Maternal serum hCG levels in triploidy: variability and need to consider molar tissue. Prenat Diagn 1992;12:627-9.
50. Saller DN Jr, Canick JA, Blitzer MG, et al. Second-trimester maternal serum analyte levels associated with fetal trisomy 13. Prenat Diagn 1999;19:813-6.
51. Spencer K, Noble P, Chan C, Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 1999;19:1035-42.
52. Spencer K, Ong C, Skentou, Liao AW, Nicolaides KH. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 2000;20:411-6.
53. Spencer K, Liao AW, Skentou H, Cicero S, Nicolaides KH. Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation, Prenat Diagn 2000;20:495-9.
54. Tint GS, Irons M, Elias ER, et al. Defective cholesterol biosynthesis associated with the Smith Lemli Opitz syndrome. N Engl J Med 1994;30:107-13.
55. Bradley LA, Palomaki GE, Knight GJ, et al. Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (SLO) syndrome fetuses. Am J Med Genet 1999;82:355-8.
56. Palomaki GE, Bradley LA, Knight GJ, Craig WY, Haddow JE. Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening for Down's syndrome. J Med Screen 2002;9:43-4.
57. Lejeune J, Gautier M, Turpin R. Etude des chromosomes somatiques de neuf enfants mongoliens. CR Acad Sci Paris 1959;248:1721-2.
58. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7(11).
59. Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides K. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 2001;358:1665-7.